The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand–a country pursuing COVID-19 elimination
| Autor: | Myra Ruka, Diana Sarfati, Ruth Pirie, Claire Hardie, Jason Gurney, John Manderson, Christopher Jackson, Michelle Mako, Alex Dunn, Richard T. North, Elinor Millar, Nina Scott |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) medicine.medical_treatment Ethnic group Cancer registration Indigenous Pandemic Internal Medicine Medicine Lung cancer COVID Cancer Service (business) Cancer services business.industry Health Policy Public Health Environmental and Occupational Health COVID-19 Obstetrics and Gynecology medicine.disease Coronavirus Radiation therapy Psychiatry and Mental health Infectious Diseases Cancer treatment Family medicine Pediatrics Perinatology and Child Health Public aspects of medicine RA1-1270 Geriatrics and Gerontology business Research Paper |
| Zdroj: | The Lancet Regional Health. Western Pacific The Lancet Regional Health. Western Pacific, Vol 10, Iss, Pp 100127-(2021) |
| ISSN: | 2666-6065 |
| DOI: | 10.1016/j.lanwpc.2021.100127 |
| Popis: | Background The COVID-19 pandemic has disrupted cancer services globally. New Zealand has pursued an elimination strategy to COVID-19, reducing (but not eliminating) this disruption. Early in the pandemic, our national Cancer Control Agency (Te Aho o Te Kahu) began monitoring and reporting on service access to inform national and regional decision-making. In this manuscript we use high-quality, national-level data to describe changes in cancer registrations, diagnosis and treatment over the course of New Zealand's response to COVID-19. Methods Data were sourced (2018–2020) from national collections, including cancer registrations, inpatient hospitalisations and outpatient events. Cancer registrations, diagnostic testing (gastrointestinal endoscopy), surgery (colorectal, lung and prostate surgeries), medical oncology access (first specialist appointments [FSAs] and intravenous chemotherapy attendances) and radiation oncology access (FSAs and megavoltage attendances) were extracted. Descriptive analyses of count data were performed, stratified by ethnicity (Indigenous Māori, Pacific Island, non-Māori/non-Pacific). Findings Compared to 2018–2019, there was a 40% decline in cancer registrations during New Zealand's national shutdown in March-April 2020, increasing back to pre-shutdown levels over subsequent months. While there was a sharp decline in endoscopies, pre-shutdown volumes were achieved again by August. The impact on cancer surgery and medical oncology has been minimal, but there has been an 8% year-to-date decrease in radiation therapy attendances. With the exception of lung cancer, there is no evidence that existing inequities in service access between ethnic groups have been exacerbated by COVID-19. Interpretation The impact of COVID-19 on cancer care in New Zealand has been largely mitigated. The New Zealand experience may provide other agencies or organisations with a sense of the impact of the COVID-19 pandemic on cancer services within a country that has actively pursued elimination of COVID-19. Funding Data were provided by New Zealand's Ministry of Health, and analyses completed by Te Aho o Te Kahu staff. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|